The Cannigma

MAY 19, 2021

In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition.

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. Investor Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc., 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MARCH 2, 2020

This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). The dawn of a new era in psychedelic medicine. Potential IPOs within the next year.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MARCH 2, 2020

In November last year, the National Institute for Health and Care Excellence (NICE) recommended 2 cannabis-based medicinal products for patients with multiple sclerosis and hard-to-treat epilepsies. In mid-April, CMC will be running a Scientific, Clinical & Regulatory Cannabinoid Conference at the British Medical Association in London. .

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Adverse events reported for these participants were mild and included fatigue, diarrhea, and nausea. . Epilepsy & behavior case reports 9 (2018): 10. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., For more information, please visit www.virpaxpharma.com. About Altasciences. Christopher M. Chipman, CPA.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Adverse events reported for these participants were mild and included fatigue, diarrhea, and nausea. [7]. Epilepsy & behavior case reports 9 (2018): 10. [4]

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

JUNE 1, 2021

Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. US Food & Drug Administration website.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Canna Law Blog

OCTOBER 5, 2022

Last year, it recommended that the government allow the use of marijuana to treat “refractory epilepsy.” ” However, that didn’t go anywhere aside from Japan quietly clearing Epidiolex for clinical trials for Dravet and Lennox-Gastaut syndromes back in 2019.

Marijuana 93

Marijuana Seed-To-Sale Clinical Trials Epilepsy 93

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. Christopher M.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. On September 9, 2021, Jeffrey A. Forward-Looking Statement.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. Robert Schatz. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax has acquired the exclusive worldwide rights from Nanomerics to use its MET platform for the nasal delivery of CBD for the management of epilepsy in children (a rare pediatric disease) and adults.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 1, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the intranasal delivery of a pharmaceutical-grade Schedule V cannabidiol (CBD) for the management of epilepsy in children, a rare pediatric disease. For more information, please visit www.virpaxpharma.com. About Noble Capital Markets, Inc. Christopher M. Chipman, CPA.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. MET technology is also used in AnQlar™, a candidate to inhibit viral replication caused by influenza or SARS-CoV-2.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

SMPL

MAY 26, 2020

We were talking about, ‘What can we do with this?’ ” recalled Samantha Miller, who hosted the event at her split-level house, wedged between redwoods and a creek below. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. The Stanleys told me their wait-list peaked at 15,000 names.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

The Cannigma

MAY 7, 2021

This is where the crux of the issue is, if you are a patient then you have epilepsy or your child has epilepsy, you want a qualified product that you can rely on that has the same level of provision in relation to the manufacturing process as any other medicine that you would take. That’s the kind of stakeholders who participate.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Cannabis Law Report

JULY 15, 2022

The schedule eight pharmaceutical medicine has gained federal approval to treat conditions including cancer-related pain, nausea and vomiting, multiple sclerosis and epilepsy, and for use in palliative care. Media event date: 27 August 2019. Most important to have your clinical trials based on the genetics of your plants.

Medicine 52

Medicine Patients Media Supply Chain 52